.avif)
.avif)
.avif)
Intercept Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
201-500 employees
・
Morristown, NJ, USA
Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat rare and serious liver diseases worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@interceptpharma.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2002
Headquarters
Morristown, NJ, USA
Revenue
$250M-$500M
FUNDING Stage
Subsidiary
Website
Key Executives
Vivek Devaraj (President - US and Chairman), Rocco Venezia (Chief Financial Officer), William Wallace (Chief Information Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Intercept Pharmaceuticals?
Intercept Pharmaceuticals uses the first.last format, so Jane Smith would be jane.smith@interceptpharma.com.
What rare liver diseases does Intercept Pharmaceuticals focus its research on?
Intercept Pharmaceuticals concentrates on rare and serious liver diseases with high unmet need, leveraging its expertise in bile acid biology and Farnesoid X Receptor (FXR) agonism to develop novel therapeutics for conditions such as cholestatic and inflammatory liver diseases.
Who leads Intercept Pharmaceuticals as President in 2026?
Vivek Devaraj serves as President, US and Chairman of Intercept Pharmaceuticals in 2026. He brings over 28 years of international pharmaceutical experience, primarily built within the Novartis group across Sandoz and other divisions.
How can I find and verify contact details for an Intercept Pharmaceuticals employee?
Intercept Pharmaceuticals uses the first.last@interceptpharma.com email format for its 277 employees based in Morristown, NJ. A tool like Clay can help you verify a specific contact's address or enrich prospect records before reaching out.
Is Intercept Pharmaceuticals an independent company or a subsidiary in 2026?
Intercept Pharmaceuticals is a wholly owned subsidiary of Italian pharmaceutical company Alfasigma S.p.A., which completed its acquisition of Intercept in November 2023 for approximately $794 million, giving Alfasigma a major hepatology presence in the US market.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating